ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, establishing a safe, ...
ImmunityBio (IBRX) shares gained on Friday after the cancer drug developer announced the successful conclusion of two manufacturing engineering programs designed to validate its Cytokine-Enriched NK ...
A newly discovered genetic switch may allow scientists to dramatically amplify the cancer-killing power of natural immune cells by harnessing the body’s own signaling molecules. Credit: Shutterstock ...
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine ...
CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc., a leading immunotherapy company, today announced early findings from the first five recurrent glioblastoma patients treated with its ...
Decreasing hypoxia with mitochondrial inhibition in locally advanced rectal cancer: Phase 1 trial of papaverine in combination with radiation (DINOMITE). This is an ASCO Meeting Abstract from the 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results